Ozempic vs Mounjaro
Published Jul 4, 2026 · 4 minute read
Ozempic and Mounjaro are the two heavyweight type 2 diabetes injections. They are different molecules, and unusually for this space, they were actually tested directly against each other. That head-to-head trial is what makes this comparison especially clear.
Key Takeaways
- Ozempic and Mounjaro are both approved for type 2 diabetes, but they are different molecules.
- Ozempic is semaglutide (a GLP-1 agonist); Mounjaro is tirzepatide (a dual GIP/GLP-1 agonist).
- SURPASS-2 was a genuine head-to-head trial: all three tirzepatide doses beat semaglutide 1 mg on A1C and weight.
- That trial compared against semaglutide 1 mg, which was the maximum Ozempic dose at the time.
- Both are once-weekly injections; their weight-management siblings are Wegovy and Zepbound.
- This page is educational and is not medical advice.
1. The Short Answer
Both Ozempic and Mounjaro are approved for type 2 diabetes, but they are built on different active ingredients.
| Ozempic | Mounjaro | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Receptors targeted | GLP-1 | GIP + GLP-1 |
| Maker | Novo Nordisk | Eli Lilly |
| Schedule | Once weekly | Once weekly |
| Weight-management sibling | Wegovy | Zepbound |
For the molecule deep dive, see Semaglutide vs Tirzepatide.
2. Same Goal, Different Molecule
Ozempic and Mounjaro share a primary purpose, type 2 diabetes, but use different mechanisms:
- Ozempic (semaglutide): a single GLP-1 receptor agonist.
- Mounjaro (tirzepatide): a dual GIP/GLP-1 receptor agonist.
3. The SURPASS-2 Head-to-Head
Most GLP-1 comparisons rely on separate trials, but Ozempic and Mounjaro’s molecules were compared directly in SURPASS-2, a 40-week trial in adults with type 2 diabetes on metformin. All three tirzepatide doses produced greater A1C reductions than semaglutide 1 mg.
One important detail: SURPASS-2 used semaglutide 1 mg, which was the maximum Ozempic dose available at the time. Ozempic later added a higher 2 mg dose, so the comparison reflects the doses studied, not every option available today.
4. The Four-Brand Map
Each diabetes brand has a weight-management sibling using the same molecule.
See also Semaglutide vs Tirzepatide for the active-ingredient comparison behind these brands.
5. How to Keep It Straight
- Ozempic = semaglutide, one receptor, Novo Nordisk.
- Mounjaro = tirzepatide, two receptors, Eli Lilly.
- Both are diabetes brands; their weight-management twins are Wegovy and Zepbound.
6. Tracking Either One
For personal records, log the brand, molecule, dose, timing, and injection site consistently, alongside glucose or lab values you choose to record. See the Ozempic tracking guide and Mounjaro tracking guide.
7. Ozempic vs Mounjaro FAQ
Are Ozempic and Mounjaro the same?
No. Both are approved for type 2 diabetes, but they are different molecules. Ozempic is semaglutide from Novo Nordisk, and Mounjaro is tirzepatide from Eli Lilly.
Did Ozempic and Mounjaro go head to head in a trial?
Yes. The SURPASS-2 trial directly compared tirzepatide (the Mounjaro molecule) against semaglutide 1 mg (the Ozempic molecule) over 40 weeks in adults with type 2 diabetes. All three tirzepatide doses produced greater A1C and weight reductions than semaglutide 1 mg.
Which lowers A1C more, Ozempic or Mounjaro?
In SURPASS-2, tirzepatide reduced A1C more than semaglutide 1 mg (about 2.0 to 2.3 percent versus 1.86 percent). Note the comparison used the 1 mg semaglutide dose available then; Ozempic later added a higher 2 mg dose. Trial averages describe populations, not individuals, and this is not medical advice.
Do Ozempic and Mounjaro have weight-loss versions?
Yes. The same molecules are sold under weight-management brands: semaglutide as Wegovy, and tirzepatide as Zepbound.
Are both once-weekly injections?
Yes, both Ozempic and Mounjaro are once-weekly injections. Semaglutide also has oral tablet forms (Rybelsus and an oral Wegovy pill); tirzepatide is currently injectable only.